Welcome to our dedicated page for Bionano Genomics news (Ticker: BNGO), a resource for investors and traders seeking the latest updates and insights on Bionano Genomics stock.
Bionano Genomics, Inc. (NASDAQ: BNGO) regularly issues news and updates about its genome analysis technologies, financial results and scientific collaborations. The company describes itself as a provider of optical genome mapping (OGM) solutions, diagnostic services and software that support research and clinical research applications in areas such as inherited disease, reproductive disorders, hematologic malignancies, solid tumors and rare diseases.
On this page, readers can follow Bionano’s announcements about quarterly and annual financial results, capital markets transactions, and strategic shifts in its business model. Recent press releases have discussed the company’s focus on routine users of its OGM solutions, trends in consumables and software utilization, and public offerings of common stock and warrants disclosed through SEC filings and corresponding news releases.
Bionano’s news flow also highlights scientific and clinical research progress involving OGM. The company frequently reports on studies presented at major conferences such as the American Society of Human Genetics (ASHG) and the Association for Molecular Pathology (AMP), where researchers have described OGM’s use in detecting structural variants across a range of genetic conditions. In addition, Bionano has drawn attention to peer-reviewed publications, including work from The University of Texas MD Anderson Cancer Center comparing OGM with targeted RNA-sequencing in acute leukemia.
Updates from Bionano Laboratories, the company’s CLIA-certified laboratory business, cover developments in OGM-based laboratory developed tests and reimbursement, including Category I CPT codes 81195 and 81354 for OGM applications in hematologic malignancies and constitutional genetic disease. Investors and researchers can use this news page to review BNGO’s historical and ongoing disclosures about its technology platforms, research collaborations, reimbursement milestones and financial performance.
Bionano Genomics, Inc. (Nasdaq: BNGO) announced a study highlighting the use of optical genome mapping (OGM) in analyzing changes in two induced pluripotent stem cell (iPSC) lines, WTC-11 and Tuba1-GFP, over 150 days. The research revealed significant genomic alterations, including hundreds of structural variants (SVs) undetected by traditional cytogenetic methods. This supports OGM's potential in regenerative medicine while raising concerns about the limitations of long-term iPSC culture. The findings accentuate OGM's value in pharmaceutical research and drug development.
Bionano Genomics (BNGO) announced the issuance of US Patent No. 11,359,244 on June 14, 2022, which covers methods for analyzing small nucleic acid fragments in nanochannel arrays. This patent relates to Bionano’s Saphyr® system, aiding in the detection of various genetic abnormalities. The technology could lead to future applications in non-invasive prenatal testing and oncology. The patent strengthens Bionano's intellectual property portfolio in genome analysis.
Bionano Genomics (BNGO) announced its participation in the EACR 2022 Congress in Seville, Spain, from June 20-23, 2022. The event will showcase Bionano's Saphyr system, NxClinical software, and expert services focused on cancer research. Key presentations will highlight the application of Optical Genome Mapping (OGM) in solid tumor analysis, including insights into pediatric CNS tumors and Ewing sarcoma. The latest NxClinical software update enhances genomic analysis capabilities for clinical researchers. This event aligns with Bionano's mission to enhance clinical research tools for cancer diagnostics.
Bionano Genomics (BNGO) showcased its Long String VANTAGE automation solution for Ultra High Molecular Weight DNA extraction at the ESHG 2022 Conference, aimed at enhancing optical genome mapping (OGM) capabilities. The collaboration with Hamilton signifies a major leap in laboratory automation efficiency. The conference featured 13 presentations highlighting OGM's role in identifying rare undiagnosed genetic diseases. CEO Erik Holmlin emphasized the potential benefits of OGM as a cost-effective and rapid alternative to traditional methods.
Bionano Genomics partnered with Hamilton to develop the Long String VANTAGE, an automated system for isolating Ultra High Molecular Weight (UHMW) DNA, enhancing throughput and quality. This innovation allows the extraction of up to 12 UHMW DNA samples in under 4 hours, double the manual output, ensuring high consistency. The collaboration aims to improve optical genome mapping applications and plans to test the system with select clinical laboratories for commercial release by the end of 2022. This automation is expected to enhance workflow efficiency in genomic analysis.
Bionano Genomics (Nasdaq: BNGO) announced a study published in Cell showcasing the effectiveness of optical genome mapping (OGM) in detecting inversions linked to genetic disorders. The research found that 80% of larger detected inversions were balanced and associated with various health issues, including pediatric autism. Analyzing 41 human samples, the study identified 40 recurrent inversions affecting 0.6% of the genome. Erik Holmlin, CEO, emphasized that OGM could make inversion analysis routine in genetic diagnostics.
Bionano Genomics (BNGO) has announced a two-hour presentation on Optical Genome Mapping (OGM) technologies by researchers from leading institutions at the Canadian College of Medical Geneticists (CCMG) General Meeting 2022, scheduled from June 6-10. The workshop, titled New Technologies and Applications of Optical Genome Mapping, will take place on June 8, featuring esteemed presenters from Columbia University Medical Center and University Health Network. This highlights Bionano's commitment to advancing genomic research and applications related to prenatal testing and cancer diagnostics.
Bionano Genomics (BNGO) will actively participate in the AGBT General Meeting 2022 in Orlando, Florida, from June 6-9. Dr. Alka Chaubey, the chief medical officer, will deliver a spotlight presentation on June 8, addressing the integration of Optical Genome Mapping (OGM) and Next Generation Sequencing (NGS) for enhanced genome analysis. Bionano is also a Bronze Sponsor and will host an evening reception, unveiling a partnership with Ignite Worldwide to promote equity in STEM. Attendees can explore live demonstrations of the Saphyr system and NxClinical software.
Bionano Genomics (Nasdaq: BNGO) announced the publication of a peer-reviewed study demonstrating the efficacy of optical genome mapping (OGM) in identifying genetic aberrations in pediatric acute myeloid leukemia (AML). Conducted by researchers at University Hospital Essen, the study analyzed samples from 24 patients, revealing that OGM detected significantly more structural variants (SVs) than traditional methods like FISH. Notably, 32 previously unknown variants were identified, with one being a high-risk marker exclusive to OGM. This research highlights OGM's potential in tracking minimal residual disease (MRD) markers crucial for treatment management.
Bionano Genomics, Inc. (BNGO) will participate virtually in the 2022 H.C. Wainwright Global Investment Conference. The presentation will be available on-demand starting May 24, 2022, at 7:00 a.m. Eastern Time. Erik Holmlin, PhD, President and CEO, will provide a company overview. Bionano specializes in optical genome mapping solutions and diagnostic software, aiming to transform genome analysis in research and medicine. Interested individuals can register for the conference and access the presentation online.